I'm calling BS on this. Come on people, get with the program, this piece was NOT put out by the shorts. It very clearly says on pages 68 and 69 that this piece was commissioned by NWBO:
The author, First Berlin, or a company associated with First Berlin reached an agreement with the Northwest Biotherapeutics Inc. for preparation of a financial analysis for which remuneration is owed.
And I am absolutely fine with that information. This sort of issuer-sponsored research is quite a common occurrence for micro/ small-cap OTC traded stocks as it helps bridge the coverage gap. Unfortunately on the OTC we live in coverage void and this paid-for-piece helps explain the science and the runway in financial speak. NWBO's technology and the DCVax-L trial are undeniably complex and this clearly helps explain the company and the science in a perspective Wall St can understand more easily. As a number of people have pointed out, this document in itself is a quality short term prospectus for the company and for investors potentially looking to invest at this juncture.
There are of course a good number of likely upcoming post-MA catalysts that simply can't be taken into account to their financial model or price target. So while $1 is certainly seems disappointing for many to see, it is a short term stepping stone until post-MA news hits. Stop pushing utter nonsense, it is as bad as the FUDsters!
AI
Market Data 
Markets 
